

Supplemental Digital Content 1

Table 2. Baseline Characteristics of the *ILIAD*E (ANRS 118) patients participating in the immunologic substudy (N=30 for IL2 and control group).

	IL2	Control
Age: median (IQR)	42 (38;36)	44 (37;50)
Gender (% female)	1 (3)	8 (27)
Nadir CD4⁺ (/mm³): median (IQR)	336 (272;480)	337 (252;372)
CD4⁺ (/mm³): median (IQR)	771 (629;876)	705 (580;802)
Proviral DNA (log copies / 10⁶ PBMC): median (IQR)	2.5 (2.2;2.8)	2.6 (2.2;2.8)
NRTI (%)	30 (100)	30 (100)
NNRTI (%)	18 (60)	15 (50)
PI (%)	7 (23)	10 (33)
Time on ARV (years): median (IQR)	5.5 (4.2;7.0)	5.3 (4.2;7.1)

Table 3. Dynamics of viral and immunological markers in 3 patients immediately after antiretroviral treatment interruption (W24): 54012 (IL2), 59022 (control with late viral rebound), 59024 (control with early viral rebound). ANRS 118/NIH 04-I-0018 ILIAD Trial.

Patient	Timing	HIV RNA (cp/mL)	CD4+ T cell count /μL	CD25+ cell /μL (%)	T count	%HLA-DR+ (among CD4+ T cells)	%CD38+ (among CD4+ T cells)
54012	W24	<40	1854	211 (11.4)		2.7	2.2
54012	W25	<40	1367	76 (5.6)		2.1	1.9
54012	W26	85	1963	320 (16.3)		2.8	2.5
54012	W28	31874	1500	429 (28.6)		4.3	3.7
59022	W24	<40	498	208 (41.9)		29.4	7.9
59022	W25	<40	495	201 (40.7)		24.1	2.3
59022	W26	<40	485	91 (18.8)		14.8	9.3
59022	W28	134	420	253 (60.2)		27.3	2.3
59024	W24	<40	516	209 (40.5)		3.0	5.8
59024	W25	<40	639	174 (27.3)		5.7	6.2
59024	W26	30300	342	41 (11.9)		11.3	10.1
59024	W28	379000	434	54 (12.5)		6.4	4.3